Deshpande Abhishek, O'Brien Joseph, Hamilton Betty, Pappas Matthew
Cleveland Clinic.
Res Sq. 2024 Jul 10:rs.3.rs-4531064. doi: 10.21203/rs.3.rs-4531064/v1.
Hematopoietic cell transplantation (HCT) recipients are at increased risk of developing primary and recurrent infection (CDI). The objective of our study was to characterize the risk factors for primary and recurrent CDI in a large cohort of patients hospitalized for HCT.
We conducted a retrospective cohort study of adults who underwent HCT from 2010-2023 to analyze the epidemiology, timing, and risk factors for CDI. We compared patients who developed CDI with those who did not, controlling for patient demographics, comorbidities, transplant factors, medications, and laboratory values.
Of the 2,725 adults who underwent HCT, 252 (9.3%) developed primary CDI within one-year of transplantation. The incidence was higher among allogenic HCT recipients (17.8%) compared to autologous recipients (4.1%). Independent risk factors for primary CDI included receipt of penicillin antibiotics, prior chemotherapy, and umbilical cord stem cells. Receipt of macrolide antibiotics was an independent risk factor for recurrent CDI, while receipt of autologous HCT was associated with a reduced risk of both primary and recurrent CDI.
CDI presents an early complication after HCT, particularly in allogenic recipients who experience higher incidence rates and severe complications. Early recognition and management of these risk factors are essential to prevent these adverse outcomes.
造血细胞移植(HCT)受者发生原发性和复发性艰难梭菌感染(CDI)的风险增加。我们研究的目的是确定一大群因HCT住院的患者中发生原发性和复发性CDI的危险因素。
我们对2010年至2023年接受HCT的成年人进行了一项回顾性队列研究,以分析CDI的流行病学、发生时间和危险因素。我们将发生CDI的患者与未发生CDI的患者进行比较,同时控制患者的人口统计学特征、合并症、移植因素、药物治疗和实验室检查值。
在2725名接受HCT的成年人中,252人(9.3%)在移植后一年内发生原发性CDI。与自体造血细胞移植受者(4.1%)相比,异基因造血细胞移植受者的发病率更高(17.8%)。原发性CDI的独立危险因素包括接受青霉素类抗生素、既往化疗和脐带干细胞移植。接受大环内酯类抗生素是复发性CDI的独立危险因素,而接受自体造血细胞移植与原发性和复发性CDI的风险降低相关。
CDI是HCT后的早期并发症,尤其是在发病率和严重并发症发生率较高的异基因造血细胞移植受者中。早期识别和管理这些危险因素对于预防这些不良后果至关重要。